In clinical practice, we have utilized expression of CD9 (in conjunction with other markers) primarily in follow-up AML samples to assist in determining whether the myeloid blast population is abnormal, looking for whole population shifts and comparing the HSCs to the CMPs. The gene discussed is CD9; the disease is acute myeloid leukemia.